Volume 31, Supplement 2, 137S-141S, DOI: 10.1007/BF01309339

Published in partnership with the

Logo

Gastroenterology Research Group

Gastric protection by misoprostol against 1300 mg of aspirin
An endoscopic study

Fred E. Silverstein, Michael B. Kimmey, David R. Saunders and Douglas S. Levine

View Related Documents

Abstract

Misoprostol, a synthetic prostaglandin E1 analog is being evaluated in the treatment of peptic ulcer. It has been reported to have both antisecretory and cytoprotective properties. In this placebo-controlled, double-blind study, pretreatment with 200-mgrg doses of misoprostol was evaluated in the prevention of gastric injury caused by aspirin. Five oral doses of misoprostol or placebo were administered over 24 hr followed by a single oral 1296-mg dose of aspirin 30 min after the fifth dose of test agent. Two hours later the gastric mucosa was examined with a small-caliber fiberendoscope. Protection was defined as no more than 10 petechiae and no more than two hemorrhagic streaks in the gastric mucosa. Twenty of 30 (67%) subjects who received misoprostol was protected, whereas only one of 30 (3%) subjects receiving placebo was protected. The difference between the effects of misoprostol and placebo was highly significant (P<0.001). we="" concluded="" that="" five="">mgrg doses of misoprostol given over 24 hr protects the gastric mucosa from the injurious effect of a single dose of aspirin.
Financial support was provided by G. D. Searle & Co., NIH Training Grant 5 T32 AMO 7113-11, NIH Program Project Grant P01 AM32971, and Fujinon Instrument Company.

Fulltext Preview

Image of the first page of the fulltext document